Quang Pham Biography and Net Worth

Chairman & Chief Executive Officer of Cadrenal Therapeutics

Quang Pham has served as our Chief Executive Officer since he formed the Company. He previously served as Chairman & CEO of Espero BioPharma, Inc., a company he also founded and the previous sponsor of the tecarfarin IND. He then served as a consultant to HESP LLC, the assignee for Espero to Horizon Technology Finance. Previously, Mr. Pham was a partner with D+R LATHIAN, LLC, a life sciences multichannel marketing agency. Prior to joining D+R LATHIAN, he founded and served as Chairman and CEO of Lathian Systems, Inc., a digital and database marketing company serving the pharmaceutical industry until 2012 when the company was acquired by D&R Communications, LLC. He has a Bachelor of Arts in Economics from UCLA, and served as a U.S. Marine Corps Officer. We believe Mr. Pham is qualified to serve on our Board of Directors because of his significant business, mergers and acquisitions, and fundraising experience, numerous interactions with the FDA, continuous six-year history with tecarfarin development, and his extensive knowledge of the pharmaceutical industry and our competitors.

What is Quang X. Pham's net worth?: The estimated net worth of Quang X. Pham is at least $90.80 thousand as of June 29th, 2026. Mr. Pham owns 98,589 shares of Cadrenal Therapeutics stock worth more than $90,800 as of October 9th. This net worth evaluation does not reflect any other investments that Mr. Pham may own. Learn More about Quang X. Pham's net worth.
How do I contact Quang X. Pham?: The corporate mailing address for Mr. Pham and other Cadrenal Therapeutics executives is 822 A1a North, Suite 306, Ponte Vedra, FL, 32082. Cadrenal Therapeutics can also be reached via phone at 904-300-0701 and via email at [email protected]. Learn More on Quang X. Pham's contact information.
Has Quang X. Pham been buying or selling shares of Cadrenal Therapeutics?: Quang X. Pham has not been actively trading shares of Cadrenal Therapeutics in the last ninety days. Most recently, Quang X. Pham sold 7,400 shares of the business's stock in a transaction on Monday, June 29th. The shares were sold at an average price of $3.03, for a transaction totalling $22,422.00. Following the completion of the sale, the chief executive officer now directly owns 98,589 shares of the company's stock, valued at $298,724.67. Learn More on Quang X. Pham's trading history.
Are insiders buying or selling shares of Cadrenal Therapeutics?: During the last year, insiders at the sold shares 31 times. They sold a total of 120,570 shares worth more than $641,841.17. The most recent insider tranaction occured on June, 29th when CEO Quang X Pham sold 7,400 shares worth more than $22,422.00. Insiders at Cadrenal Therapeutics own 14.6% of the company. Learn More about insider trades at Cadrenal Therapeutics.
Information on this page was last updated on 6/29/2026.

Quang X. Pham Insider Trading History at Cadrenal Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/29/2026	Sell	7,400	$3.03	$22,422.00	98,589
6/26/2026	Sell	9,029	$3.05	$27,538.45	105,989
6/25/2026	Sell	2,127	$3.00	$6,381.00	115,018
6/23/2026	Sell	2,277	$3.20	$7,286.40	117,145
6/22/2026	Sell	9,167	$3.55	$32,542.85	119,422
6/17/2026	Sell	513	$3.16	$1,621.08	128,589
6/16/2026	Sell	3,613	$3.18	$11,489.34	129,102
6/15/2026	Sell	3,666	$3.58	$13,124.28	132,715
6/12/2026	Sell	12,996	$3.94	$51,204.24	136,381
6/11/2026	Sell	1,462	$4.12	$6,023.44	149,377
6/10/2026	Sell	3,500	$4.21	$14,735.00	150,839
6/9/2026	Sell	12,992	$4.06	$52,747.52	154,339
6/8/2026	Sell	5,893	$4.38	$25,811.34	167,331
6/5/2026	Sell	2,064	$4.42	$9,122.88	173,224
6/4/2026	Sell	3,898	$4.41	$17,190.18	175,288
6/3/2026	Sell	2,323	$4.26	$9,895.98	179,186
6/2/2026	Sell	349	$4.46	$1,556.54	181,509
5/29/2026	Sell	303	$5.01	$1,518.03	181,858
5/28/2026	Sell	2,989	$4.93	$14,735.77	182,161
5/22/2026	Sell	1,165	$5.69	$6,628.85	194,924
5/12/2026	Sell	3,298	$5.28	$17,413.44	185,150
5/11/2026	Sell	6,476	$5.76	$37,301.76	188,448
10/27/2025	Sell	1,315	$13.99	$18,396.85	196,089
10/24/2025	Sell	1,129	$14.03	$15,839.87	197,404
10/13/2025	Sell	1,800	$14.15	$25,470.00	198,533
10/9/2025	Sell	1,800	$14.02	$25,236.00	200,333
10/2/2025	Sell	500	$14.13	$7,065.00	202,133
10/1/2025	Sell	881	$14.01	$12,342.81	202,633
9/29/2025	Sell	419	$14.01	$5,870.19	203,514
9/25/2025	Sell	6,790	$14.09	$95,671.10	203,933
9/24/2025	Sell	2,581	$13.99	$36,108.19	210,723
8/28/2025	Sell	1,193	$13.99	$16,690.07	213,304
8/27/2025	Sell	3,836	$13.99	$53,665.64	214,497
9/1/2023	Buy	70,000	$0.91	$63,700.00	3,370,000

Quang X. Pham Buying and Selling Activity at Cadrenal Therapeutics

Cadrenal Therapeutics Company Overview

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Today's Range

Now: $0.92

$0.90

$0.97

50 Day Range

MA: $1.41

$0.93

$2.03

2 Week Range

Now: $0.92

$0.85

$14.50

Volume

63,736 shs

Average Volume

192,673 shs

Market Capitalization

$3.27 million

P/E Ratio

N/A

Dividend Yield